Daily News Podcast

TNF inhibitor linked to one-third drop in total mortality

Publish date: June 18, 2018

 

Receiving a TNF inhibitor for any indications cut patients’ overall mortality rate by more than one-third. Also today, HHS secretary, Alex Azar blames pharmacy benefit managers for no drop in prescription prices, a DEA ruling may have stoked illicit opioid sales, and taking a bisphosphonate holiday that lasts 2 years or longer is linked with increased risk for fracture.

Listen to the MDedge Daily News podcast for all the details on today’s top news.

Recommended Reading

Smoking tied to localized prostate cancer recurrence, metastasis, death
MDedge Rheumatology
FDA approves rituximab for treating pemphigus vulgaris
MDedge Rheumatology
EMEUNET network of young rheumatologists keeps moving forward
MDedge Rheumatology
Suicide rate jumps 30%
MDedge Rheumatology
New cell-free DNA assays hold promise for lung cancer screening
MDedge Rheumatology
Allergies linked to autism spectrum disorder in children
MDedge Rheumatology
Study finds widespread use of medications with depression as side effect
MDedge Rheumatology
Type 2 diabetes may promote Parkinson development
MDedge Rheumatology
FDA database reveals many rheumatic and musculoskeletal adverse events on immunotherapies
MDedge Rheumatology
Routine AAA screening for older men: more harm than good?
MDedge Rheumatology